Navigation Links
Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
Date:9/15/2008

BERKELEY HEIGHTS, N.J., Sept. 15 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced today that the independent Data Monitoring Board (DMB) for AGENDA, a Phase 3 trial of the Company's lead oncology product Genasense(R) (oblimersen sodium) Injection, has completed its review. During its review, the DMB evaluated safety data from the study and conducted an analysis for futility. With more than half of the initially planned number of patients now enrolled, the Board recommended that the trial continue to completion of full enrollment.

AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from Genta's prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients identified by a biomarker who have not previously received chemotherapy. The co-primary endpoints of AGENDA are progression-free survival and overall survival. A total of 300 patients are expected to enroll in AGENDA.

Genta will provide a pooled update of blinded data from AGENDA, compared with data obtained in this biomarker-defined population from the Company's previous Phase 3 trial (see below), at an international scientific meeting, Perspectives in Melanoma XII, that is scheduled for October 2-4, 2008.

"We remain quite pleased with the high investigator enthusiasm for AGENDA," said Dr. Loretta M. Itri, M.D., Genta's President, Pharmaceutical Development. "We currently anticipate that accrual will complete in the first quarter of 2009."

About AGENDA

AGENDA employs a biomarker to define those patients who derived maximum clinical benefit during a large randomized study of DTIC with or without Genasense, known as study GM301. These patients are characterized by low-normal levels of LDH (lactate dehydrogenase), a tumor-derived enzyme that
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom
5. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
6. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
7. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R)
8. Kiwa Fertilizers Pass Independent Tests
9. Amarin Appoints Dr. William Mason as Lead Independent Director
10. China Pharma Appoints Three Independent Non-Executive Directors
11. China Technology Appoints Deloitte Touche Tohmatsu CPA as Independent Auditor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Argentina Biomedical Sensors Market - Growth, Trends ... The Argentina Biomedical Sensors market is estimated ... 1.17% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cbgl72/middle_east_and ) has announced ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Middle East & Africa Biomedical ... at a CAGR of 3.26% over the period 2014-2020 ... that are adaptable to the genetic formulation of each ...
(Date:8/31/2015)... Mass. , Aug. 31, 2015  RXi ... company focused on discovering and developing innovative therapies ... today announced that the 30-day review period following ... (IND) for ocular indications with the U.S. Food ... IND is now active. Logo ...
(Date:8/31/2015)... , Aug. 31, 2015 FLX Bio, Inc., ... of novel cancer immunotherapies, announced today that it has ... Executive Officer and William Ho , M.D., Ph.D., ... an experienced management team led by veterans of Flexus ... Ph.D., Chief Scientific Officer; Jay Powers , Ph.D., ...
Breaking Biology Technology:Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4
... 28, 2011 Qteros, Inc., the developer of a ... platform for the lowest-cost production of cellulosic ethanol, today ... throughout the month of May. Kevin A. ... for Qteros, will deliver an oral presentation at the ...
... 2011 Omnicare Clinical Research (CR), a leading global, ... has been acquired by Nautic Partners, LLC, a private ... the deal not only makes official the separation of Omnicare ... the company,s most visible step in a comprehensive two-year ...
... April 28, 2011 Reportlinker.com announces that ... in its catalogue: Case ... of biomarker identification and companion diagnostic co-development ... Introduction The ...
Cached Biology Technology:Qteros Management to Present at Upcoming Conferences in May 2Omnicare Clinical Research Acquired by Nautic Partners, LLC 2Omnicare Clinical Research Acquired by Nautic Partners, LLC 3Reportlinker Adds Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development 2Reportlinker Adds Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development 3
(Date:8/28/2015)... , August 28, 2015 ... and Training Market by Assessment Type (Pen & Paper ... Brain Training, Corporate Learning, Academic Research), Vertical and Region ... Assessment and Training Market to grow from USD 2.4 ... at a Compound Annual Growth Rate (CAGR) of 25.6% ...
(Date:8/25/2015)... CITY and BELLEVUE, Wash. ... leader in advanced robotic systems, announced today it will ... unmanned ground vehicle (UGV), at the National Tactical Officers ... The Guardian S is the first-ever ... culmination of years of research and in-field trials and ...
(Date:8/24/2015)... 24, 2015  Based on its recent analysis of the ... 2015 African Biometrics Company of the Year Award. DERMALOG is ... success in Africa . It has particularly ... has implemented one of the largest biometric mass applications in ... the Central Bank of Nigeria with ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6
... all terrorist attacks from 1970 to 2008 occurred in just ... rural areas, spurred on by domestic actors, according to a ... the Study of Terrorism and Responses to Terrorism (START), a ... based at the University of Maryland. The research was ...
... Nature Genetics today has found new evidence for ... 2 diabetes. The study found that people who carry rare ... higher risk of type 2 diabetes. The findings should ... could lead to the development of personalised treatments. Previous ...
... Nature Climate Change today finds that tropical vegetation ... Using a combination of remote sensing and field data, scientists ... University of Maryland were able to produce the first "wall-to-wall" ... m) of carbon storage of forests, shrublands, and savannas in ...
Cached Biology News:5 US urban counties lead 'Terror Hot Spots' list, but rural areas not exempt 25 US urban counties lead 'Terror Hot Spots' list, but rural areas not exempt 3Body clock receptor linked to diabetes in new genetic study 2The good news about carbon storage in tropical vegetation 2The good news about carbon storage in tropical vegetation 3
Liquid. 50 μg/ml in PBS, pH 7.4. PROTECT FROM LIGHT. A convenient form of propidium iodide useful for flow cytometry studies. RTECS SF7949600, CAS 25535-16-4, M.W. 668.4. ...
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... VersArray ChipWriter Pro systems are ... proteins, or other biological samples. VersArray ... for uniformity, spot density, and reproducibility ... a variety of substrates. Their modular ...
Thermal printer paper is used with the thermal printer for the VersaFluor fluorometry systems. Supplied as 10 rolls....
Biology Products: